uniQure (NASDAQ:QURE) Price Target Raised to $10.00 at The Goldman Sachs Group

uniQure (NASDAQ:QURE) had its price target raised by The Goldman Sachs Group from $6.00 to $10.00 in a report published on Friday, Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock.

Several other analysts also recently issued reports on QURE. Mizuho cut their price objective on uniQure from $7.00 to $6.00 and set a neutral rating on the stock in a report on Wednesday, May 8th. Cantor Fitzgerald restated an overweight rating and set a $24.00 price objective on shares of uniQure in a report on Tuesday, July 16th. Finally, HC Wainwright restated a buy rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $18.60.

uniQure Price Performance

NASDAQ QURE traded down $0.17 on Friday, reaching $7.31. The company’s stock had a trading volume of 1,130,627 shares, compared to its average volume of 7,764,378. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 9.39 and a quick ratio of 9.27. The firm’s 50 day moving average is $6.02 and its two-hundred day moving average is $5.53.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). uniQure had a negative net margin of 1,027.52% and a negative return on equity of 137.05%. The business had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. As a group, equities research analysts forecast that uniQure will post -4.4 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

Large investors have recently made changes to their positions in the business. Sectoral Asset Management Inc. bought a new stake in shares of uniQure in the 4th quarter valued at approximately $1,981,000. Bridger Management LLC boosted its position in uniQure by 2,917.3% during the fourth quarter. Bridger Management LLC now owns 362,349 shares of the biotechnology company’s stock worth $2,453,000 after purchasing an additional 350,340 shares during the period. Acadian Asset Management LLC boosted its position in uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after purchasing an additional 350,291 shares during the period. Vontobel Holding Ltd. boosted its position in uniQure by 458.5% during the fourth quarter. Vontobel Holding Ltd. now owns 295,042 shares of the biotechnology company’s stock worth $1,997,000 after purchasing an additional 242,214 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in uniQure by 74.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock worth $818,000 after purchasing an additional 66,958 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.